Clinical trial
GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
NCT00252876 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00252876 |
|---|---|
| Title | GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes |
| Official title | An Open-Label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 1 mg in Patients With Type 2 Diabetes Mellitus. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | tesaglitazar |
| Enrollment | 2,000 |
| Start date | Mar 1, 2005 |
| Completion | Jan 1, 2007 |
| First posted | Nov 15, 2005 |
| Last update posted | Mar 17, 2008 |
| Countries | Argentina, Australia, Brazil, Canada, Czechia, Estonia, Finland, Greece, Hong Kong, Hungary, India, Indonesia and 19 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: